|Bid||93.28 x 800|
|Ask||93.49 x 800|
|Day's Range||92.01 - 93.92|
|52 Week Range||81.66 - 100.15|
|Beta (3Y Monthly)||0.66|
|PE Ratio (TTM)||26.27|
|Forward Dividend & Yield||2.00 (2.25%)|
|1y Target Est||N/A|
May 24, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced that it will participate in the Bernstein 35th Annual Strategic Decisions Conference on Wednesday, May 29, 2019, in New York City. Omar Ishrak, chairman and chief executive officer of Medtronic, will make a presentation and will answer questions about the company beginning at 10:00 a.m. EDT (9:00 a.m. CDT). Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world`s largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world.
Q4 Revenue of $8.1 Billion, Flat as Reported and Grew 3.6% Organic Q4 GAAP Diluted EPS of $0.87; Q4 Non-GAAP Diluted EPS of $1.54 FY19 Revenue of $30.6 Billion Grew 2.0% Reported and 5.5% Organic FY19 ...
The data indicate that renal denervation (RDN) with the Medtronic Symplicity(TM) renal denervation system was associated with reduced occurrence of subclinical atrial fibrillation (AF) in a small subset of high-risk patients with hypertensive heart disease over a median follow-up period of more than two years. Results from the single-center, randomized, sham-controlled study were presented today during a Late-Breaking Clinical Trial session at the 2019 EuroPCR Annual Meeting in Paris. The investigator-led study funded by Medtronic randomized 80 patients to either the renal denervation procedure with the Symplicity renal denervation system or a fake "sham" procedure.
FDA Cleared and CE Marked, Telescope Enters Global Market with Design Innovations to Enable Smooth Delivery of Coronary Stents and Balloons DUBLIN - May 16, 2019 - Medtronic plc (NYSE:MDT), a global leader ...
Company to Proceed with Plans for Future Pivotal Study of New ICD System DUBLIN and SAN FRANCISCO - May 11, 2019 - Medtronic plc (NYSE:MDT) today announced findings from a pilot study of its investigational ...
May 10, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, including implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT), often do not receive needed therapy. The findings underscore gender and race treatment disparities, as well as a lack of referrals to physicians to implant the devices. Presented at Heart Rhythm 2019, the Heart Rhythm Society`s 40th Annual Scientific Sessions, the analyses were supported by Medtronic plc (MDT) and used Optum® Electronic Health Records (EHR) datasets and algorithms developed as part of the Medtronic GLIDE HF (GuideLine Indications Detected in EHR for HF) initiative.
May 10, 2019 - Medtronic plc (MDT) announced today that it will report financial results for its fourth quarter and fiscal year 2019 on Thursday, May 23, 2019. The news release will include summary financial information for the company`s fourth quarter and fiscal year 2019, which ended on Friday, April 26, 2019. Medtronic will host a webcast at 7:00 a.m. CDT to discuss financial results for its fourth quarter and full fiscal year 2019.
May 9, 2019 - Medtronic plc (MDT), a global leader in medical technology, today announced that it has entered into a definitive agreement pursuant to which it will acquire Titan Spine, a privately-held titanium spine interbody implant and surface technology company. The boards of directors of both companies have unanimously approved the transaction. Terms of the transaction are not being disclosed.
May 9, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced the publication of the SMILE study in The Lancet Diabetes & Endocrinology.1 The SMILE study (Study of MiniMed 640G Insulin Pump with SmartGuardTM in prevention of Low Glucose Events in adults with Type 1 diabetes) is the largest randomized controlled trial to investigate the effectiveness and safety of the MiniMed(TM) 640G system with SmartGuard(TM) Suspend before low technology compared to insulin pump therapy without continuous glucose monitoring (CGM) in decreasing hypoglycemia (low blood sugar). The study was conducted with adults with type 1 diabetes (T1D) prone to severe hypoglycemia, a condition that can cause confusion, disorientation, loss of consciousness, seizures, and in the worst cases can result in coma or death.
To Assess the Potential of Non-Opioid Treatment Options for Chronic Pain, Study Evaluates Pain Relief, Patient Function and Satisfaction DUBLIN and LAS VEGAS - May 7, 2019 - Medtronic plc (NYSE:MDT) today ...
May 2, 2019 - Medtronic plc (MDT) today announced that the company has received U.S. Food and Drug Administration (FDA) approval for the CareLink SmartSync(TM) Device Manager. With the introduction of SmartSync, physicians will now be able to use an Apple® iPad® to program and manage data from Medtronic`s BlueSync-enabled implanted cardiac devices.
May 1, 2019 - Medtronic plc (MDT) announced it has received U.S. Food and Drug Administration (FDA) approval for the Attain Stability(TM) Quad MRI SureScan(TM) left heart lead. Paired with Medtronic quadripolar cardiac resynchronization therapy-defibrillators (CRT-D) and -pacemakers (CRT-P), the Attain Stability Quad lead is the only active-fixation left heart lead, and is designed for precise lead placement and stability.
April 30, 2019 - Medtronic plc (MDT) today announced the U.S. launch of the Solitaire(TM) X Revascularization Device - and its first use in patients for the treatment of acute ischemic stroke. For ten years, the industry-leading Solitaire(TM) Revascularization Device has enabled physicians in helping patients have a better chance at recovering from stroke. Solitaire X is a 4th generation device featuring an optimized delivery system for improved efficiency - while retaining the technical features that have made the Solitaire family of revascularization devices clinically proven and highly effective.
April 17, 2019 - Medtronic plc (MDT) today released new data on endovascular repair of abdominal aortic aneurysm (AAA) patients with the Endurant(TM) II/IIs stent graft system in combination with Heli-FX(TM) EndoAnchor(TM) implants and for the Valiant Navion(TM) thoracic stent graft system for thoracic endovascular repair (TEVAR). The data presented at the Charing Cross Symposium in London expands on the commitment to treat increasingly challenging aortic anatomies.
April 17, 2019 - Medtronic plc (MDT) today announced five-year outcomes from the VeClose Extension Study. The new data demonstrate durable and consistent long-term outcomes of the Medtronic VenaSeal(TM) Closure System in treating patients with chronic venous disease. The VeClose Extension Study is a follow-on study with the purpose of evaluating long-term outcomes at five years post-treatment with the VenaSeal Closure System.
Positive HVAD LATERAL TM Study Results Also Now Published in The Journal of Heart and Lung Transplantation DUBLIN and ORLANDO, Fla. - April 8, 2019 - Medtronic plc (NYSE:MDT) today announced data showing ...
Savings Are Driven by Fewer Inpatient Visits, Shorter Inpatient Length of Stay, and Fewer Emergency Department Visits DUBLIN - April 8, 2019 - Medtronic plc (NYSE:MDT) today announced results of a study ...
Company Has Initiated a Post-Approval Study of Heart Failure Management Best Practices to Further Demonstrate Improved Patient Outcomes DUBLIN and ORLANDO, Fla. - April 5, 2019 - Medtronic plc (NYSE:MDT) ...
March 25, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced the launch of the Medtronic MedTech Innovation Accelerator in Pujiang International Science and Technology City at Minhang District, Shanghai. The new collaborative innovation platform will provide services for MedTech start-ups worldwide, address unmet clinical needs in China, and welcome its initial roster of portfolio companies.
Late-Breaking Trial Results Presented at ACC Scientific Sessions and Published in The New England Journal of Medicine WRAP-IT is the Largest Randomized Global Trial Ever Conducted with Cardiac Implanted ...
March 16, 2019 - Medtronic plc (MDT) today announced first-ever clinical data from the landmark Evolut Low Risk Trial comparing the minimally invasive Evolut(TM) transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients.
March 14, 2019 - Medtronic plc (MDT) today announced that its Board of Directors has appointed Andrea J. Goldsmith, Ph.D. to the Board as an independent director, effective March 11, 2019. Dr. Goldsmith is the Stephen Harris professor in the School of Engineering at Stanford University and director of Stanford`s Wireless Systems Laboratory.
March 8, 2018 - The board of directors of Medtronic plc (MDT) today approved the fiscal year 2019 fourth quarter cash dividend of $0.50 per ordinary share, representing a 9 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2018. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 41 consecutive years. In addition to approving the dividend, the board today authorized the expenditure of funds for share repurchases.
March 7, 2019 - Medtronic plc (the "Company") (MDT) today announced that its wholly-owned subsidiary Medtronic Global Holdings S.C.A. ("Medtronic Luxco") has closed a registered public offering (the "Offering") of €500,000,000 principal amount of Floating Rate Senior Notes due 2021, €1,500,000,000 principal amount of 0.000% Senior Notes due 2021, €1,500,000,000 principal amount of 0.375% Senior Notes due 2023, €1,500,000,000 principal amount of 1.125% Senior Notes due 2027, €1,000,000,000 principal amount of 1.625% Senior Notes due 2031 and €1,000,000,000 principal amount of 2.250% Senior Notes due 2039 (collectively, the "Notes"). All of Medtronic Luxco`s obligations under the Notes are fully and unconditionally guaranteed by the Company and Medtronic, Inc. ("Medtronic, Inc."), a wholly-owned indirect subsidiary of Medtronic Luxco, on a senior unsecured basis.
DUBLIN - March 6, 2019 - Medtronic plc (the "Company") (NYSE:MDT) today announced the pricing terms of the previously-announced cash tender offers by its wholly-owned subsidiaries, Medtronic, ...